Skip to main content
2026 ASCRS Annual Scientific Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Live Streamed Session
Live Streamed Session
Nurses Contact Hours
Nurses Contact Hours
Self-Assessment
Self-Assessment
Live Q&A and Polling
Live Q&A and Polling
Social
Social
Industry
Industry

Michael Overman, MD (he/him/his)

Professor
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States

I am an Associate VP in the Department of Cancer Network Research at MD Anderson Cancer Center, Houston, TX and a clinical researcher focused on intestinal cancers and the optimal conduct of clinical trials. I have developed a multi-year effort to improve understanding small bowel adenocarcinoma with multiple clinical and laboratory publications. Principle investigator (PI) for SWOG1922, first randomized clinical trial in this disease and I am PI clinical trial of nivolumab +/- ipilimumab in microsatellite instability-high (MSI-H) colorectal cancer (CRC) (CheckMate 142, NCT02060188).
In addition, my trial portfolio includes a neoadjuvant programmed cell death protein 1 (PD-1) trial in MSI-H cancers, a fecal microbiome transplantation study for PD-1 refractory MSI-H cancers and a major project with CRC/Pancreas SPORE evaluating personalized vaccine administration with optimal adjuvants to minimal residual disease CRC patients. Conducting clinical research has generated multiple publications related to clinical trial endpoint reporting (J Clin Oncol), integration of research biopsies into clinical trials (J Clin Oncol, Clin Cancer Res, and JAMA Oncol), racial reporting in FDA indication clinical trials, and a R01 concept related to activity monitoring to objectively determine Eastern Cooperative Oncology Group Performance Status (ECOG PS). These efforts lead to successful, impactful clinical trials contributions to science
1. Improving clinical research transparency - proven to improve the transparency of the quality of clinical research. This area of effort has impacted the practice of oncological trial research broadly.
2. MSI-H and immune checkpoint therapy - a limited number of patients presented in the metastatic setting with MSI-H cancer, leading to a multicenter study investigating nivolumab +/- ipilimumab in MSI-H CRC (CheckMate 142, NCT02060188), which resulted in two FDA approvals.
3. Development of a small bowel adenocarcinoma research and clinical trial program.
4. Identifying a novel mechanism of oxaliplatin-induced thrombocytopenia through clinical observations which characterize this novel finding.

Presentation(s):

Email Michael